bimatoprost / Generic mfg. - LARVOL DELTA

Nanoelectrospray fabrication of pH-responsive double-layered drug-eluting contact lenses for ocular drug delivery. (PubMed, Int J Pharm) - "In this study, bimatoprost, a drug widely used in glaucoma therapy, was selected as a model compound to develop a double-layered, pH-responsive DECL system incorporating drug-loaded NPs...In conclusion, the double-layered, nanoparticle-loaded DECLs with a pH-responsive coating effectively demonstrated sustained drug release at physiological pH, with significantly reduced drug loss during storage in packaging solution. This scalable platform has the potential for DECL manufacturing which provides an alternative ocular drug delivery solution for chronic conditions like glaucoma."

Journal • Glaucoma • Ophthalmology

Severe Microbial Keratitis Secondary to Prostaglandin-Associated Periorbitopathy. (PubMed, Case Rep Ophthalmol Med) - "Prostaglandin-associated periorbitopathy (PAP) is a known complication of prostaglandin therapy most commonly associated with topical bimatoprost...The authors report a case of PAP-induced lagophthalmos and secondary microbial keratitis that necessitated a corneal graft. Reversal of these findings occurred on prostaglandin cessation with dramatic reversal of findings within 8 weeks."

Journal • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Transplantation

The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation. (PubMed, J Clin Med) - "The eyes were stratified by preoperative FP agonist use into the high-PAP-inducing-potential (bimatoprost or travoprost) and low-PAP-inducing-potential (latanoprost or tafluprost) groups. Although the effect on AGV implantation appears limited, it may still influence early postoperative results. These findings underscore the need to consider PAP risk and medication history when selecting surgical procedures for glaucoma."

Journal • Glaucoma • Ophthalmology

STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - P3 | N=28 | Terminated | Sponsor: University of Miami | N=500 ➔ 28 | Completed ➔ Terminated; No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint.

Enrollment change • Trial termination • Glaucoma • Ophthalmology

Safety and Efficacy of a Preservative-Free Bimatoprost 0.01% Ophthalmic Gel: Results from a Phase III Controlled Trial. (PubMed, J Glaucoma) - "PF bimatoprost 0.01% ophthalmic gel was noninferior to the preserved bimatoprost 0.01% ophthalmic solution, with similar safety and tolerability over 3 months."

Journal • P3 data • Cardiovascular • Glaucoma • Ophthalmology

Investigating the role of bimatoprost in vitiligo therapy: a systematic review and meta-analysis (EADV 2025) - "Topical bimatoprost demonstrates promise as an adjunctive treatment for vitiligo, particularly in combination with modalities like narrowband UVB and fractional CO₂ laser. It offers improvements in repigmentation, surface area reduction, and patient satisfaction, with minimal adverse effects. However, its high cost and limited availability pose barriers to widespread adoption."

Retrospective data • Review • Dermatology • Glaucoma • Immunology • Ophthalmology • Pruritus • Vitiligo

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: University of Maryland, Baltimore | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Glaucoma • Ophthalmology

Estimating Costs of Market Exclusivity Extensions For 4 Top-Selling Prescription Drugs in the US. (PubMed, JAMA Health Forum) - "In the absence of extended market exclusivity, and over a 2-year period following generic competition, net spending would have decreased by $3.5 billion, including $1.9 (95% CI, $1.3-$2.5) billion in commercial plans and $1.6 (95% CI, $1.1-$2.1) billion in Medicare-including $67 (95% CI, $22-$115) million for bimatoprost, $726 (95% CI, $516-$938) million for celecoxib, $1.7 (95% CI, $1.0-$2.4) billion for glatiramer, and $1.0 (95% CI, $0.8-$1.2) billion for imatinib. This study found that promoting timely generic availability and avoiding extending market exclusivity for top-selling drugs may result in substantial savings for US patients and payers, including both public and private health insurance programs."

Journal • Retrospective data • CNS Disorders • Glaucoma • Immunology • Multiple Sclerosis • Oncology • Ophthalmology • Rheumatology

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1/2 | N=96 | Recruiting | Sponsor: AbbVie | Trial completion date: Aug 2028 ➔ Feb 2029 | Trial primary completion date: Aug 2028 ➔ Feb 2029

Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

Non-ablative 1927 nm Fractional Thulium Laser With Bimatoprost to Treat a Hypopigmented Burn Scar. (PubMed, Cureus) - "At her initial consultation, she was prescribed Ruxolitinib (a Janus Kinase (JAK) inhibitor) 1.5% (Opzelura) cream to use each morning and tacrolimus 0.1% ointment (a calcineurin inhibitor) to use every night...The laser created micro-channels for enhanced topical absorption, while the topical agents reduced inflammation and promoted melanogenesis. This combination offers a promising, non-invasive treatment for hypopigmented burn scars."

Journal • Inflammation • Ophthalmology

DoE based development and optimization of ion sensitive in situ nanoemulgel containing bimatoprost for sustained ocular delivery. (PubMed, Int J Biol Macromol) - "This novel formulation offers a competitive option to traditional eye drops because of its prolonged precorneal residence duration and sustained medication release. Pharmacodynamic evaluations demonstrated that the developed NEG formulation enriched with omega-3 fatty acids and hyaluronic acid (HA) provided superior glaucoma management while simultaneously mitigating the adverse effects commonly associated with conventional anti-glaucoma therapies."

Journal • Cardiovascular • Dry Eye Disease • Glaucoma • Ophthalmology

The Chaste Gaze: Long Thick Eyelashes as a Symbol of Divine Chastity-From Ancient Greece to Now. (PubMed, J Craniofac Surg) - "Products such as bimatoprost have further medicalized beauty...While patients may seek enhancement for aesthetic or restorative reasons, motivations often reflect deeper cultural anxieties about visibility, desirability, and self-worth. Ultimately, the eyelash emerges as a striking symbol of beauty's transformation-from divine chastity to digitally curated allure-reminding practitioners and scholars to remain conscious of the meanings embedded in aesthetic ideals across time."

Journal • Transplantation

Efficacy and safety of prostaglandin drugs for elevated intraocular pressure: a Bayesian network meta-analysis. (PubMed, Front Med (Lausanne)) - "To evaluate and compare the effectiveness and safety of latanoprost, bimatoprost, travoprost, and tafluprost in lowering intraocular pressure (IOP) in individuals with glaucoma or ocular hypertension. Latanoprost and tafluprost offered balanced efficacy with better tolerability, making them suitable for patients with mild disease. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251034803."

Journal • Retrospective data • Review • Cardiovascular • Glaucoma • Ophthalmology

Vitamin D and its Analogs in Treatment of Mild to Moderate Alopecia Areata: Systematic Review and Meta-Analysis. (PubMed, Indian Dermatol Online J) - "Vitamin D3 and its analogs may serve as a safe, inexpensive alternative for mild-to-moderate patchy AA, either as a mono-therapeutic agent or as an adjuvant for more severe cases."

Clinical • Journal • Retrospective data • Alopecia • Immunology

Bimatoprost as a Treatment for Graves' Orbitopathy (clinicaltrials.gov) - P1 | N=3 | Recruiting | Sponsor: Johns Hopkins University | Trial completion date: Jul 2030 ➔ Jul 2031 | Trial primary completion date: Jul 2028 ➔ Jul 2029

Trial completion date • Trial primary completion date • Ophthalmology • Thyroid Eye Disease

Prostaglandin F2α stimulates the growth of human intermediate hair follicles in ex vivo organ culture with potential clinical relevance. (PubMed, Front Physiol) - "The discovery that bimatoprost, a prostamide F2α analogue, stimulates eyelash growth suggest a possible role for other prostanoids in hair growth...We demonstrate, for the first time, that PGF2α stimulates human HF growth in organ culture via a receptor-driven mechanism, probably directly affecting the follicles' regulatory dermal papilla function. The greater response of intermediate, compared to matched terminal, HFs suggests potential future clinical significance for medical conditions such as alopecia, or insufficient beard growth, and promoting hair growth in 'relatively hairless' donor graft skin or transplant follicles after elective, trauma or burn injury surgical reconstruction."

Journal • Preclinical • Aesthetic Medicine • Alopecia • CNS Disorders • Dermatology • Immunology • Transplantation

Bimatoprost for the management of vitiligo: a systematic review and meta-analysis (CDA 2025) - "Bimatoprost presents as a potentially effective vitiligo treatment, showing improvements in repigmentation, surface area, and patient satisfaction, especially when in combination with therapies like narrowband ultraviolet B therapy and fractional CO2 laser. Adverse events were minimal, with hypertrichosis emerging as a limiting factor for some patients. Additionally, bimatoprost’s high cost and limited availability are barriers for widespread use."

Retrospective data • Review • Dermatology • Immunology • Pruritus • Vitiligo

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: University of Maryland, Baltimore

Biomarker • New trial • Glaucoma • Ophthalmology

Intraoperative optical coherence tomography in glaucoma surgery with Ex-PRESS® implant. (PubMed, Eur J Ophthalmol) - "Our patient was being treated with dorzolamide-timolol eyedrops twice daily and bimatoprost eyedrops once daily in both eyes. I-OCT can help surgeons to locate the correct placement of implants in cases with media opacity (such as corneal opacification or gerontoxon) or in phakic patients, where it is important to avoid lens contact. This instrument is helpful in the training of ophthalmologists."

Journal • Cataract • Glaucoma • Ophthalmology

Enhancing hair regrowth in Alopecia areata: the power duo of CO2 fractional laser and Bimatoprost. (PubMed, Arch Dermatol Res) - "This study provides a foundation for further research and highlights the potential integration of prostaglandin analogs with laser-based interventions in AA management. Future studies with larger sample sizes and extended follow-up periods are necessary to validate these promising results and assess long-term treatment sustainability."

Clinical • Journal • Aesthetic Medicine • Alopecia • Dermatology • Immunology

Prostaglandin F2α, EP2 and EP3 agonists modulate the formation of 3D organoids of human orbital adipose-derived stem cells (ARVO 2025) - "Purpose To investigate the effect of prostaglandin F2α agonist (bimatoprost), EP2 agonist (butaprost) and EP3 agonist (sulprostone) on 3D organoids of human orbital adipose-derived stem cells (OASCs) during adipogenic differentiation...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Glaucoma • Ophthalmology

Benperidol, Ecopipam, and Aclidinium Bromide as Potential Therapeutics of Congenital Primary Glaucoma (ARVO 2025) - "The current standard of treatment for PCG includes surgery as first-line, but also includes maintenance therapy with drugs such as timolol (-0.384), latanoprost (-0.31), bimatoprost (-0.469), acetazolamide (-0.330), and pilocarpine (-0.331). Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Glaucoma • Ophthalmology • CYP1B1

Pathogenic role of Thy-1 in prostaglandin-associated periorbitopathy (ARVO 2025) - "3T3-L1 cells were treated with dimethyl sulfoxide (control), 1 μM bimatoprost (BIMA), or 1 μM omidenepag isopropyl (OMDI, negative control) for 48 hours. Our study found that bimatoprost increases Thy-1 expression, driving orbital cells toward a myofibroblast fate that causes tissue tightening. These results suggest a pathological role for Thy-1 in severe PAP and provide insights for potential therapeutic strategies."

Ophthalmology • ACTA2 • THY1

Predictors of severity in prostaglandin-associated periorbitopathy. (PubMed, Cutan Ocul Toxicol) - "Among the 86 patients included in the study, 24 (27.9%) used bimatoprost, 35 (40.7%) used latanoprost, and 27 (31.4%) used travoprost. Older age, longer duration of PGA therapy, and the use of bimatoprost and travoprost were significant and independent predictors of severe PAP in patients with glaucoma. Patients with these risk factors should be identified and managed to prevent the development of severe PAP."

Journal • Cardiovascular • Glaucoma • Ophthalmology

HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation. (PubMed, J Pharm Biomed Anal) - "Some prostaglandin F2α (PGF2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF2α analogs."

Journal